Effect of JAK2^V617F (JAK2^VF) CHIP on CAD. Meta-analysis of the effects of JAK2^VF CHIP on the occurrence of CAD events in All of Us, UK Biobank, and MGB Biobank. (A) Multivariable-adjusted logistic regression model including age, square of age, sex, self-reported race, principal components of ancestry 1 to 10, smoking status, body mass index (BMI), systolic blood pressure, antihypertensive medication use, hyperlipidemia, cholesterol-lowering medication use, and prevalent diabetes mellitus as covariates. (B) Association of JAK2^VF CHIP with CAD in the presence or absence of non-JAK2^VF CHIP clones. Participants were categorized in 4 groups based on the presence of (1) JAK2^VF CHIP mutations and (2) large non-JAK2^VF CHIP mutations (ie, VAF > 10%). This figure shows the associations of each of these groups with incident CAD events in the UK Biobank, All of Us, and MGB Biobank. Effects were estimated using Cox proportional hazards models including age, square of age, sex, self-reported race, principal components of ancestry 1 to 10, smoking status, BMI, systolic blood pressure, antihypertensive medication use, hyperlipidemia, cholesterol-lowering medication use, and prevalent diabetes mellitus as covariates. Participants without CHIP (no CHIP) serving as the reference group (Ref). (C) Fixed-effects meta-analysis of the proportion of JAK2^VF CHIP across study cohorts yielded comparable estimates for participants who self-reported as White vs Black. No unadjusted (Fisher exact) or adjusted (logistic regression models adjusted for age, square of age, sex, smoking status, and BMI) tests revealed a statistically significant association of race (Black vs White) with prevalence of JAK2^VF CHIP for the individual cohorts. Fixed-effects meta-analysis of the effect of race (Black vs White) on JAK2^VF CHIP prevalence yielded a meta-analyzed multivariable-adjusted OR of 0.88 (95% CI, 0.43-1.81; P = .73).